The acquisition of Pivya is an important step in Alembic’s ability to provide branded pharmaceutical product to the US Healthcare market
Net sales for 9M FY23 up 9% to Rs. 4,246 crore and net profit for 9M FY23 at Rs. 189 crore
The amalgamation will integrate business operations and provide impetus to the existing portfolio of Alembic
The company is focused on the development of novel treatments for RNA viruses
The US business faced price erosion due to increased competition.
Subscribe To Our Newsletter & Stay Updated
